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Angiotensin converting enzyme 2 (ACE2) is a zinc carboxypeptidase involved in the renin–
angiotensin system (RAS) and inactivates the potent vasopressive peptide angiotensin II
(Ang II) by removing the C-terminal phenylalanine residue to yield Ang1–7. This conversion
inactivates the vasoconstrictive action of Ang II and yields a peptide that acts as a
vasodilatory molecule at the Mas receptor and potentially other receptors. Given the
growing complexity of RAS and level of cross-talk between ligands and their corresponding
enzymes and receptors, the design of molecules with selectivity for the major RAS binding
partners to control cardiovascular tone is an on-going challenge. In previous studiesweused
single β-amino acid substitutions to modulate the structure of Ang II and its selectivity for
ACE2, AT1R, and angiotensin type 2 (AT2R) receptor. We showed that modiﬁcation at the
C-terminus of Ang II generally resulted inmore pronounced changes to secondary structure
and ligand binding, and here, we further explore this region for the potential to modulate
ligand speciﬁcity. In this study, (1) a library of 47 peptides derived from the C-terminal
tetrapeptide sequence (-IHPF) of Ang II was synthesized and assessed for ACE2 binding,
(2) the terminal group requirements for high afﬁnity ACE2 binding were explored by and N-
and C-terminal modiﬁcation, (3) high afﬁnity ACE2 binding chimeric AngII analogswere then
synthesized and assessed, (4) the structure of the full-length Ang II analogs were assessed
by circular dichroism, and (5) the Ang II analogs were assessed for AT1R/AT2R selectivity
by cell-based assays. Studies on the C-terminus of Ang II demonstrated varied speciﬁcity
at different residue positions for ACE2 binding and four Ang II chimeric peptides were
identiﬁed as selective ligands for the AT2 receptor. Overall, these results provide insight
into the residue and structural requirements for ACE2 binding and angiotensin receptor
selectivity.
Keywords: angiotensin II, angiotensin II receptor 1, angiotensin II receptor 2, angiotensin converting enzyme-2,
β-amino acids
INTRODUCTION
Angiotensin II is the central active component of the RAS and
signals primarily through the AT1R, and production of Ang II is
catalyzed by the degradation of angiotensin by ACE. High blood
pressure, or hypertension, is the main risk factor of cardiovascu-
lar disease and so two major therapeutic targets for treatment of
hypertension are ACE and the AT1R. Although there are a number
of anti-hypertensive drugs on the market such as ACE inhibitors
(e.g., Captopril, Enalapril), and AT1R antagonists/blockers (e.g.,
Losartan, Valsartan) individual responses and side-effect pro-
ﬁles are highly variable, and often a mixed therapeutic regime
Abbreviations: ACE2, angiotensin converting enzyme 2; Ang II, angiotensin II;
AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 receptor; LC, liquid
chromatography; MS, mass spectrometry; QFS, quenched ﬂuorescence substrate;
RAS, renin–angiotensin system.
is necessary. This is largely attributable to the complexity of RAS,
the level of cross-talk between key molecules such as AngII, its
cleavage products, and their binding partners [e.g., ACE2, AT1R,
AT2R, Mas receptor (MasR, Santos et al., 2003)] and the resulting
activation of pathways downstream of receptor binding.
Angiotensin converting enzyme 2, a zinc carboxypeptidase
(Donoghue et al., 2000; Tipnis et al., 2000; Turner et al., 2002),
the AT1R and the AT2R and their Ang II-derived ligands are
all involved in modulating hypertension (Donoghue et al., 2000;
Tipnis et al., 2000; Turner et al., 2002; Jiang et al., 2014). ACE2
is also up-regulated in the heart in human and animal models
of cardiovascular disease and speciﬁcally in the human ﬁbrotic
liver [ref]. Ang1–7 is generated by the action of ACE2 (Vick-
ers et al., 2002) and is now considered a major component of
RAS and has been shown to exert speciﬁc actions via binding
to MasR (Santos et al., 2003, 2008; Bader et al., 2014). A number
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of compounds have been developed that inhibit ACE2 activ-
ity [DX600/MLN4760, Millennium Pharmaceuticals, Cambridge,
MA, USA (Dales et al., 2002)], or activate activity (Hernandez
Prada et al., 2008). Someof theseACE2 inhibitors have been shown
to increase cardiac hypertrophy and ﬁbrosis (Trask et al., 2010)
while ACE2 activators have been shown to have signiﬁcant anti-
hypertensive action and be effective in the reversal of cardiac and
renal ﬁbrosis (Varagic et al., 2014). Given the central role of ACE2
in inactivating Ang II and generating Ang1–7, a more detailed
description of the molecular speciﬁcity of AngII–ACE2 interac-
tion is important. Knowledge on how Ang II analogs with altered
ACE2 binding speciﬁcity act at the AT1R and AT2R is useful to
identify compounds with selective action for potential therapeutic
use.
We previously described the inﬂuence of single β-amino acid
substitutions on the structure andbindingofAng II toACE2 (Clay-
ton et al., 2011). We demonstrated that three different regions of
Ang II that exert different effects on Ang II structure and binding,
namely the N-terminus, the central and the C-terminal region. We
also showed that the β-turn conformation is the structural deter-
minant for enhanced substrate cleavage. In this previous study the
C-terminus was the most susceptible to changes and in the present
study we have further explored the structural requirements of this
region of Ang II in regards to ACE2 and AT receptor binding. We
hypothesized that the C-terminus of Ang II is the main binding
determinant for ACE2, and here we further explore this speciﬁcity,
and also the speciﬁcity of Ang II for its other binding partners
(AT1R and AT2R) by residue substitution in the C-terminus of
Ang II. The structural requisites for binding to these different pro-
tein targets were also explored by circular dichroism (CD) analysis
of the Ang II analogs.
MATERIALS AND METHODS
CHEMICALS
General peptide synthesis reagents were purchased from GL
Biochem (Shanghai, China) and AusPep (Melbourne, VIC, Aus-
tralia), high purity acetonitrile from Merck (Whitehouse Station,
NJ, USA), and high purity formic acid for LC–MS from Fluka
(Sigma-Aldrich, St. Louis, MO, USA). β-amino acids were
from Peptech (Burlington, MA, USA) and the ACE2 QFS from
AusPep.
PEPTIDE SYNTHESIS
Angiotensin II, β-substituted and C-terminal tetrapeptide analogs
were prepared using Fmoc solid-phase peptide synthesis (SPPS)
approaches on Wang resin using standard side chain protecting
groups. Generally, a 3-fold excess of amino acid and HATU, and
4.5-fold excess of DIPEA with a coupling time of 30 min was
used for manual synthesis. The extent of the amino acid cou-
plings was monitored using the ninhydrin reaction (Sarin et al.,
1981). Amidated Ang II tetrapeptides were made on Rink Amide
resin (Novabiochem/Merck-Millipore) and N-terminal acetyla-
tion was performed for 10 min with a 10% acetic anhydride, 2%
DIPEA, DMF solution. Microwave-assisted peptide synthesis was
performed on a CEM Liberty system (USA, NC) using a 5-fold
excess of amino acid and HBTU with 5 min irradiated coupling
times. Peptides were cleaved from the resin and deprotected with
a TFA cleavage solution (TFA/TIPS/H2O, 95:2.5:2.5), for 2 h at
room temperature.
HPLC PURIFICATION AND ANALYSIS
Angiotensin II analogs were puriﬁed by RP–HPLC from crude
peptide, on an Agilent (Agilent Technologies, Palo Alto, CA, USA)
HP1200 system using a Vydac, 10 × 250 mm C4 column. Lin-
ear gradients were from 10 to 25% acetonitrile (0.1% TFA). All
peptides were identiﬁed by MS an MSD VL3000 ion-trap mass
spectrometer (Agilent Technologies, Palo Alto, CA, USA). Purity
of the peptides was determined by RP–HPLC on a 150 × 4.6 mm
C18 column. Ang II analogs were exchanged to the chloride salt
for QFS assays by re-dissolving them in a 15-fold excess of aqueous
HCl, 10 min standing, followed by lyophilization. Peptides were
then re-dissolved in 50% acetonitrile/water and re-lyophilized to
yield a white powder.
ACE2 QUENCHED FLUORESCENCE SUBSTRATE (QFS) ASSAYS
Angiotensin converting enzyme 2 QFS assays were performed for
1 h in 50 uM QFS, 1 M NaCl, 100 mM Tris-Cl, pH 6.5 at 37
◦
C on a
BMG LabTechnologies (Offenburg, Germany), FLUOStar Optima
in a 96 well-plate. Subsequent data analysis determined the inhibi-
tion of nativeAngII, its analogs andC-terminal peptides compared
to the ACE2 QFS substrate [MCA-APK(DNP)-OH, Vickers et al.,
2002]. Initially, analogs were screened in triplicate at 100 μM and
those showing signiﬁcant inhibition as compared to control pep-
tides, either AngII (DRVYIHPF), or the C-terminal IHPF, were
then assayed at concentrations of 10 μM or lower. Three con-
trols were included in each ACE2 QFS assay; AngII (100 and
10 μM), IHPF (100 μM) and a known ACE2 inhibitor (1 nM;
Millennium Pharmaceuticals, Cambridge, MA, USA). QFS assay
results were accepted whenACE2 inhibition byAngII (10 μM) was
80 ± 5%, IHPF was 65 ± –5% and the (Qian et al., 1999) ‘Millen-
nium Inhibitor’was 70± –5%. Acceptable coefﬁcients of variation
(CV; standard deviation/mean × 100) for sample triplicates
were <7%.
CIRCULAR DICHROISM
Circular dichroism measurements were performed on a Jasco J-
810 Circular Dichroism Spectropolariser (Jasco, Tokyo, Japan)
using quartz cuvettes of 1 mm path length. Scans between 190
and 260 nm were performed at a scan speed of 20 nm/min, band-
width of 1.0 nm, resolution of 0.1 nm, a 1 s response time and
with three scan accumulations. The quartz cuvette temperature
was controlled (25◦C) with a Peltier temperature controller and
the CD instrument was calibrated with (+)-10-camphorsulfonic
acid. CD spectra of Ang II and β-analogsweremeasured in /10mM
phosphate buffer at 7.0, and spectra were smoothed using the Jasco
Fast Fourier transform algorithm and then baseline corrected.
Peptide concentration was approximately 200 μM for each ana-
log. The concentration of each solution was normalized by peak
integration at 214 nm by RP–HPLC to ensure similar concentra-
tion for each peptide solution. Furthermore, the CD spectra of the
individual aromatic amino acids present in Ang II were recorded
free in solution at similar concentration and then subtracted from
the spectra of the Ang II analogs to minimize the contaminating
CD signal from aromatic side chains.
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LC–MS ACE2 PROTEOLYTIC CLEAVAGE ASSAY
Angiotensin II analogs (10 μM) were incubated at 37◦C in the
presence of ACE2 until over a half of theAng II control was cleaved
(as determined by LC–MS), typically between 4 and 5 h then pro-
teolysis was quenched by the addition of 40 μl of 4 M urea/50%
acetonitrile/0.2% triﬂuoroacetic acid. The ﬁrst hour of the incuba-
tion was performed in the Fluorostar Optima plate reader in order
to conﬁrm previously observed level of inhibition, then for the
remaining time the samples were transferred to small microfuge
tubes and incubated in a water bath. The extent of ACE2 cleav-
age was assessed by LC–MS on an Agilent capillary HP1100, MSD
VL3000 Ion-Trap system.
ANGIOTENSIN RECEPTOR BINDING EXPERIMENTS
The generation of plasmids expressing HA-tagged versions of the
AT1R andAT2R have been previously described Qian et al. (1999),
D’Amore et al. (2005). HEK-293 cells in 12 well-plates were trans-
fected with either AT1R or AT2R plasmids (0.6 μg/well) using
lipofectAMINE (4·8 μl/well), as previously described Thomas
et al. (1998) and stably expressing clones obtained by selection
with G418 (1 mg/ml) and limiting dilution. HEK clones express-
ing eitherAT1RorAT2Rwere plated in 12well-plates forwhole cell
competition binding assays using the non-selective Ang II ligand,
[125I]-Ang II and selected concentrations of Ang II, PD123319
(an AT2-selective ligand) and the various β-substituted Ang II
peptides. Non-linear regression of the data was achieved using
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA)
to determine relative displacement of chimeric Ang II analogs as
compared to 125I-Ang II in either AT1R- or AT2R- transfected
HEK-293 cells.
RESULTS
Ang II-ACE2 BINDING REQUIREMENTS
A library of 40 tetrapeptides based on the four C-terminal residues
of Ang II (Ile-His-Pro-Phe/IHPF) was generated and screened for
ACE2 binding at 100 μM in order to identify key residues of the
C-terminus of Ang II involved in binding to the ACE2 active site.
Peptide sequences and the apparent binding values are listed in
Table 1. ACE2 binding was assessed indirectly by use of a QFS
assay where the ability of the compound to reduce the proteolytic
cleavage of a ﬂuorogenic substrate shows relative ACE2 binding
(Clayton et al., 2011). Several substitutions (Val, Tyr, Ala, Gly, Phe,
Trp, Pro, His, Ile, and Leu) were made in order to further probe
the highly hydrophobic and cyclic speciﬁcity of the C-terminus of
Ang II. A β-napthalene amino acid (Nth) derivative was used as
a highly hydrophobic non-natural cyclic residue substitute, and
Arg and Lys were substituted for histidine at the second position
from the N-terminus of the tetrapeptide to determine if posi-
tive charge or other structural or positional requirements were
important.
The requirements for ACE2 binding at the ﬁrst position of the
tetrapeptide [fourthposition from theAng IIC-terminus (XHPF)]
were a preference for non-polar, hydrophobic or cyclic residues,
with Val and Pro substitutions showing enhanced binding [both
78% inhibition (Inh.)], and Ala showing similar binding (59%
Inh.) compared to the native C-terminal of Ang II (IHPF, 62%
Inh.). Large bulky functional groups were less tolerated at this
Table 1 | Angiotensin converting enzyme 2 inhibition of single
substitution analogs of the C-terminal of AngIIa,b,c,d,e.
Substitution (X) XHPF IXPF IHXF IHPX
AngII C-terminal – IHPF
Valine (V) 78 28 77 18
Tyrosine (Y) 34 87 1 50
Alanine (A) 59 37 19 44
Glycine (G) 0 39 0 41
Phenylalanine (F) 48 0 0
Tryptophan (W) 0 40 0 57
Proline (P) 78 0 – *
Histidine (H) 12 – 14 54
Isoleucine (I) – 32 44 36
Leucine (L) – – 0 48
Napthaline (Npth) 18 39 53 55
Lysine (K) – 28 – –
Arginine (R) – 33 – –
Unmodiﬁed Angiotensin II sequence – H2N- DRVY - IHPF -COO(-).
aThe position of the substitution is indicated as ‘X’ and in bold at top of col-
umn, bpeptides screened at 100 μM, cnative IHPF C-terminal shows 62% Inh. at
100 μM, dnapthaline represents a β-napthalene amino acid analog and, eslightly
negative values observed have been assigned as 0% inhibition. *Synthesis of
IHPP was attempted twice but unsuccessful.
position with substantial reductions in ACE2 binding observed
when tryptophan or a naphthalene-derived amino acid was placed
at this position (0, 18% Inh.). Interestingly, substitution of the
minimal amino acid residue Gly to this position abolished ACE2
binding.
No strict preference was observed at position two of the
tetrapeptide (IXPF, the third position from the C-terminus), with
a range of analogs able to bind ACE2 and inhibit QFS cleavage
(Val, Ala, Gly, Trp, Ile, and Nth, 28–40% Inh.). The two residues
not tolerated at this position were the apolar cyclic residues Phe
and Pro, which showed no ACE2 binding at 100 μM. Interestingly,
when another hydrogen bond donating side chain, tyrosine, was
substituted at this position, ACE2 binding was enhanced (IYPF
87%, IHPF 62% Inh.). ACE2 binding was completely abolished by
substitution of either Phe or Pro to this position (0% Inh.) while
substitution of the His for other positively charged residues also
resulted in moderate reductions in ACE binding (Arg 33%, Lys
28% Inh.).
The most stringent side chain requirements were seen for the
third position of the tetrapeptide (IHXF, the second position from
the C-terminus), or the P1’ site of the scissile-bond with only three
out of the ten substitutions tolerated. Substitution of Val or Ile to
this position resulted in either moderate increases (Val, 77% Inh.)
or decreases (Ile, 44% Inh.) to ACE2 binding. The other func-
tional group tolerated at this position was napthalene with this
analog showing a slight decrease in ACE2 binding (53% Inh.). The
observation that two of the three residues tolerated at this posi-
tion are β-branched amino acids indicates some peptide structural
constraint, or conferred conformation is a requirement for ACE2
www.frontiersin.org January 2015 | Volume 6 | Article 5 | 3
Clayton et al. Selective ACE2 and ATR ligands
binding. All other analogs at this position showed minimal or
substantially reduced binding with Tyr, Gly, Phe Trp, His, Ala, or
Leu showing between 0 and 19% inhibition.
Minimal speciﬁcity was observed for residues at the C-terminal
residue, or at the P1 site of the scissile-bond. All substitutions at
this position exhibited some level of ACE2binding,with the largest
decrease observed when Val was tested at the ﬁrst residue (18%
Inh.). Other substitutions, ranging from compact (Gly/Ala), bulky
(Nth/Trp), apolar (Ile/Leu) to a polar (His) side chain were toler-
ated with only minor to moderate decreases in binding observed
(36 to 57% Inh. vs. 62% IHPF).
By combining the optimal substitutions at the ﬁrst, second
and third positions in IHPF, seven tetrapeptide analogs were gen-
erated of which three showed almost equivalent ACE2 binding
compared to the full-length native Ang II (Ang II 97% Inh.,
PYPF/PHVF/PYVF 93/94% Inh.; peptide sequences and binding
data listed in Table 2). These three analogs showed almost saturat-
ing levels of inhibition at the screening concentration of 100 μm.
Three further modiﬁcations were made to these seven peptides,
and to the control peptide IHPF, to probe the binding require-
ments of the termini and assess the binding of these C-terminal
analogs in the absence of a potentially shielding N-terminal pos-
itive charge; N-terminal acetylation, C-terminal amidation and,
the combination of both modiﬁcations. These terminally mod-
iﬁed peptides which are listed in Table 3, were ﬁrst screened at
100 μM, and the peptides that retained high levels of binding
were then screened at 10 μM to further evaluate ACE2 binding
(Table 3). Although N-terminal acetylation removes the positive
charge and enhances hydrophobicity, and thus was anticipated
to enhance ACE2 interaction, both increases and decreases in
inhibition were observed. The only clear trend was that N-
capping an analog with an N-terminal Pro always resulted in
decreases in ACE2 inhibition. The largest decrease in ACE2 bind-
ing was seen when the PHVF analog was acetylated (8% Inh.
at 100 μM), while other N-terminal Pro analogs showed more
moderate decreases. Three N-capped peptides showing increased
Table 2 | Angiotensin converting enzyme 2 inhibition of multiple
residue substitution analogsa,b,c.
Single
substitutions
Inhibition (%) Multiple
substitutions
Inhibition (%)
FromTable 1 VYPF 90
VHPF 78 PYPF 93
PHPF 81 VHVF 85
IYPF 84 PHVF 93
IHVF 77 IYVF 77
VYVF 78
PYVF 94
Unmodiﬁed Angiotensin II sequence – H2N- DRVY - IHPF -COO(-).
Residue substitutions shown in underlined and in bold; apeptides screened at
100 μM, bmultiple substitution based on optimal single residue substitutions at
ﬁrst, second and third position, cnative IHPF C-terminal shows 62% inhibition at
100 μM.
Table 3 | Angiotensin converting enzyme 2 inhibition of terminally
modified IHPF analogsa.
AngII analog Unmodified N -acetylated C-amidated N -acetylated/
C-amidated
100 (10) μM 100 (10) μM 100 (10) μM 100 (10) μM
IHPF 66 (22) 87 (41) 18 26
PHPF 81 (20) 57 1 8
IYPF 84 (35) 93 (62) 8 18
VYPF 78 (26) 98 (79) 25 30
PYPF 93 (50) 87 (44) 33 28
VHVF 85 (37) 76 (31) 86 (40) 21 (4)
PHVF 93 (49) 8 12 12
PYVF 94 (51) 78 (18) 26 25
Unmodiﬁed Angiotensin II sequence is – H2N- DRVY – IHPF -COO(-).
aAnalogs were ﬁrst screened at 100 μM, then those showing inhibition greater
than IHPF (66%) were screened at 10 μM (in brackets).
binding were, IHPF (87% Inh. vs. 66% unmodiﬁed), IYPF (93
vs. 84% unmodiﬁed) and VYPF (98 vs. 78% unmodiﬁed), while
other analogs showed minor to moderate decreases in binding
(Table 3).
As expected, the presence of a C-terminal carboxylate was
required to maintain high levels of ACE2 binding, with moder-
ate to large decreases (1–33% Inh.) in binding observed for all
but one C-terminally amidated analogs (Table 3). TheVHVF ana-
log showed no change (86% Inh. vs. 85% Inh. unmodiﬁed) in
ACE2 binding even though the C-terminal carboxylate is abol-
ished, indicating a distinct mode of binding for this compound.
The only amidated analog whose ACE2 binding was substantially
altered by N-terminal capping was VHVF, which showed a 4-fold
reduction in ACE2 inhibition by QFS assays. This indicates the
N-terminal positive charge of this peptide may play a key role in
binding for this analog, either through direct interaction or via
structural stabilization. Assessing Ang II analogs at less saturat-
ing concentrations (10 μM) was performed to better characterize
the relative ACE2 binding differences of the modiﬁed peptides
(Table 3; 10 μM data shown in brackets). This revealed the largest
increases in ACE2 binding for acetylated IYPF and acetylated
VYPF, which showed a three to 4-fold overall increase in bind-
ing (62 and 79% Inh.) as indicated by QFS assays. Other peptides
showed more moderate increases to ACE2 binding.
In summary, based on the results for the Ang II C-terminal
analogs, signiﬁcant increases in apparent binding to ACE2 were
observed for substitution of isoleucine by proline or valine at the
ﬁrst position of IHPF, tyrosine for histidine at the second position,
and valine for proline at the third position. Combinations of these
favorable single residue substitutions generally resulted in fur-
ther increases in apparent ACE2 binding. N-terminal acetylation
of the most potent tetrapeptides resulted in increased inhibition
for many peptides while C-terminal amidation greatly diminished
apparent binding of all but one of these tetrapeptides,VHVF. The
tetrapeptides having the highest binding to ACE2 had IC50 values
in the 5–20 μM range (full-length AngII, IC50, ∼5 μM).
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ACE2 BINDING OF Ang II CHIMERAS
ChimericAng II analogswere prepared by combining key elements
of ACE2 binding and proteolytic stability identiﬁed in previ-
ous experiments. These peptides contained the most inhibitory
acetylated C-terminal tetrapeptides (Table 3) grafted to the native
N-terminal sequence of Ang II to further enhance ACE2 binding
and are listed in Table 4. Two β-amino acid analogs of Ang II
which stabilize the scissile-bond (β-Pro7 and β-Phe8) in Ang II
(Clayton et al., 2011) were also tested for comparative purposes
(Table 4).
Enhancements to apparent ACE2 inhibition were observed
when the native N-terminal sequence was combined with the most
inhibitory C-terminal sequences. The Ang II chimera DRVYIYPF
showed 96% inhibition at 10 μM (Table 4) as compared to the
acetylated peptide IYPF (Table 3, 62% at 10 μM), and showed
notably more inhibition than the native Ang II (77% at 10 μM).
DRVYVYPF also showed increased levels of ACE2 inhibition com-
pared to the capped VYPF, showing 98% inhibition (Table 4)
as compared to 79% (Table 3). This Ang II chimera also exhib-
ited increased apparent ACE2 binding compared to native Ang II
which exhibited 77% inhibition at 10 μM. Signiﬁcant decreases
in binding were observed when β-Pro was substituted at the
scissile-bond of both these Ang II chimeras; the ACE2 inhibi-
tion of DRVYIYβPF decreased to 10% while that of DRVYVYβPF
decreased to 42%. Notable drops in ACE2 binding were also seen
for the two β-Phe Ang II analogs with binding completely abol-
ished in DRVYIYPβF and 15% inhibition (Table 4) observed for
Table 4 | Angiotensin converting enzyme 2 inhibition and cleavage of
AngII chimerasa,b.
100 μM 10 μM 1 μM 0.1 μM
Inhibition (%)
AngII (DRVYIHPF) 99 ± 0.3 77 ± 2.9 21 ± 6.8 –5 ± 8.1
DRVYIYPF – 96 ± 0 78 ± 2 17* ± 6
DRVYVYPF – 98 ± 0.3 84 ± 2.7 31 ± 3.5
DRVYIYβPF 72 ± 1.5 10 ± 5.8 –4 ± 9.8 –
DRVYVYβPF 90 ± 0.6 42 ± 4.4 0 ± 11.4 –
DRVYIYPβF 53 ± 1.9 0 ± 5 –1 ± 6.8 –
DRVYVYPβF 59 ± 2.1 15 ± 9 2 ± 3.6 –
Cleavage (%)
AngII (DRVYIHPF) – 40* ± 2 93 –
DRVYIYPF – 18 ± 1.2 85 –
DRVYVYPF – 9 ± 0.3 64 –
DRVYIYβPF 0 ± 0 0 ± 0 – –
DRVYVYβPF 0 ± 0 0 ± 0 – –
DRVYIYPβF 0 ± 0 0 ± 0 – –
DRVY,VYPβF 0 ± 0 0 ± 0 – –
Unmodiﬁed Angiotensin II sequence – H2N- DRVY - IHPF -COO(-).
aPeptides were assayed for ACE2 inhibition at 10 and 1 μM, and for ACE2 pro-
teolytic cleavage at 10 μM then depending on their inhibition levels at either
higher or lower concentrations; bACE2 proteolytic cleavage assessed over 4 h.
*Averages are based on two replicate values.
the DRVYVYPβF analog. Notable decreases in ACE2 inhibition
were also observed for β-Pro and β-Phe substitutions in native
Ang II in a previous study (Clayton et al., 2011). Native Ang II and
chimeric analogs showing high levels of ACE2 binding at 10 μM
were then assessed at reduced concentration, ﬁrst at 1 μM and
then at 0.1 μM if measurable inhibition was observed. The two
non-β-amino acid analogs, DRVYIYPF and DRVYVYPF, retained
signiﬁcant levels of ACE2 binding when assessed at lower concen-
tration with 17 and 31% inhibition observed at 0.1 μM [Table 4 –
native AngII, 21% Inh. at 1 μm, no (–5%) Inh. at 0.1 μM].
Analogs that showednotable reductions in apparentACE2 binding
(Table 2, inhibition data) were assayed at an increased concentra-
tion of 100 μM in order to adequately assess ACE2 proteolytic
stability.
All Ang II chimeras showed increased ACE2 proteolytic stabil-
ity when assessed by RP–HPLC, though with reductions to ACE2
binding also observed for several peptides. DRVYIYPF showed
96% inhibition at 10 μM and 18% cleavage over 5 h as compared
to 40% cleavage of native Ang II (Table 4). DRVYVYPF showed
even more enhanced proteolytic stability with approximately 4-
fold less (9%) cleavage by ACE2 over 5 h compared to native
Ang II (40%). β-Pro and β&-Phe Ang II analogs, DRVYIYβPF,
DRVYVYβPF, DRVYIYPβF, and DRVYVYPβF showed complete
resistance to proteolytic cleavage at a concentration where sub-
stantial ACE2 binding occurred (Table 4, 100 μm cleavage data).
DRVYVYβPF is the AngII analog showing the highest levels of
ACE2 binding (42%, 10 μM) and showing complete proteolytic
stability to ACE2.
SECONDARY STRUCTURE DETERMINED BY CD
Circular dichroism spectra of native Ang II in mixtures of TFE
and water at pH 7.0 indicate elements of both β-turn and α-
helical structure with minima between 205 and 220 nm and with
a stronger absorbing CD component around 190 nm (Figure 1A).
A broad CD signal present between 220 and 245 nm is consis-
tent with the presence of mixed β-sheet and β-turn conformation.
Substitution of the histidine residue by tyrosine (DRVYIYPF)
and further substitution of isoleucine to valine (DRVYVYPF)
resulted in a slightly more pronounced 220 nm minima and
the disappearance of the broad signal at 230–240 nm, suggest-
ing a loss of the β-sheet and β-turn components and more
pronounced helical conformation (Figure 1A). Inclusion of a β-
proline, an extension to the peptide backbone by one methylene
group, to the second residue from the C-terminal for either of
these analogs (DRVYIYβPF and DRVYVYβPF) resulted in struc-
tural changes with a notable decrease in the helical content as
indicated by the loss of CD signal at ∼220 nm. (Figure 1B).
As the maximum at 190–195 nm is still present, it is likely
that a signiﬁcant amount of stabilized secondary structure is
still present (such as a mixture of β-sheet or β-turn struc-
ture particularly given the red-shifted random coil minima and
a broad CD signal in the observed 205–220 nm wavelength
range) though further analysis is required given the complex
spectra that can arise from mixtures of secondary structure.
Notably different structural changes were observed when a β-
amino acid was introduced at the C-terminal phenylalanine
for DRVYIYPβF and DRVYVYPβF; Figure 1B) with distinct
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FIGURE 1 | Circular dichroism (CD) spectra of chimeric AngII analogs.
(A) Shows the CD spectra of native AngII and two C-terminal non-β-amino
acid analogs (DRVYIYPF, DRVYVYPF) in 25% triﬂuoroethanol (TFE) and
10 mM phosphate buffer. (B) Shows four β-amino acid analogs (βPro and
βPhe, scissile-bond is between Pro and Phe residues AngII sequence) of
DRVYIYPF and DRVYVYPF in similar mixtures of TFE and aqueous
phosphate buffer.
minima at 217/218 nm and maxima at 190–195 nm suggesting α-
helical structure together with a possible β-sheet-like component
(Greenﬁeld, 2006a,b).
ANGIOTENSIN RECEPTOR BINDING
The chimeric Ang II peptides and their β-analogs were screened
for binding to AT1 and AT2 receptors (AT1R and AT2R) up
to saturating concentration to determine the relative receptor
selectivity. The results are listed in Table 5 and revealed dif-
ferent binding properties of these peptides for each receptor,
with all but one analog showing dramatic losses in binding
to the AT1R while AT2R binding varied in the range from
25% to a value similar to that of native Ang II. Substitution
of histidine for tyrosine and/or isoleucine for valine resulted
in complete loss of AT1R binding and this was also seen for
both the β-Pro analogs of these peptides. Of the two β-Phe
analogs, the double substitution analog (DRVYVYPβF) showed
no AT1R binding, while the single substitution analog showed
∼30% binding compared to native Ang II (Table 5). AT2R
Table 5 | Relative binding of various Ang II analogs to AT1R andAT2R.
Peptide sequence AT1Rbinding (%)a AT2Rbinding (%)a
D1R2V3Y4I5H6P7F8 >95 >95
D1R2V3Y4I5Y6P7F8 0 >95
D1R2V3Y4V5Y6P7F8 0 >95
D1R2V3Y4I5Y6βP7F8 0 80
D1R2V3Y4V5Y6βP7F8 0 75
D1R2V3Y4I5Y6P7βF8 30 25
D1R2V3Y4V5Y6P7βF8 0 25
Unmodiﬁed Angiotensin II sequence – H2N- DRVY - IHPF -COO(-).
aAT receptor binding shown as % compared to native AngII binding (which repre-
sents 100%displacement) concentration of 14C labeled receptor binding peptide.
% binding as determined at 1 μM concentration.
binding requirements were shown to be less stringent than
AT1R binding as all Ang II analogs had some level of AT2R
binding, with both the single and double non-β-amino acid
substitutions exhibiting similar binding as native Ang II. Small
decreases in AT2R binding were observed for both of the β-Pro
analogs, with 80 and 75% binding observed for the single and
double substitution analogs, respectively. Substantial decreases
in binding were seen when the C-terminal Phe residue was
replaced with its β-analog with reductions to receptor binding of
∼75% observed for both single and double substitution peptides
(Table 5).
DISCUSSION
The conventional wisdom that maximum blockage of RAS results
in the best therapeutic outcome is now considered an over-
simplistic model, and the molecular detail of key binding partners
in RAS is also poorly understood. Thus, in spite of the large num-
ber of anti-hypertensive agents on the market, new therapeutic
approaches are always required to meet the challenges of per-
sonalized medicine with minimal side-effects. A more detailed
description of the molecular binding interactions and RAS lig-
and binding speciﬁcities will facilitate understanding this complex
system and facilitate drug design.
Angiotensin converting enzyme 2, AT1R and AT2R all play a
central role in this constantly evolving scenario and our stud-
ies provide new insight into the structure and function of these
proteins. We have investigated the topographical and structural
requirements for the binding of the C-terminal region of Ang II to
ACE2, AT1R, and AT2R. We employed a focused library approach
to characterize the binding determinants in the Ang II C-terminal
tetrapeptide template IHPF. The results identiﬁed four substitu-
tions that enhanced apparent binding to ACE2. A series of seven
tetrapeptide analogswas then generatedwhich all exhibited signiﬁ-
cant binding at 10μM.Apparent bindingdata revealed thatVal and
Pro at position 1, Tyr in position 2, and Val in position 3 of IHPF
yielded maximum binding. N-terminal acetylation increased the
apparent binding for the parent IHPF and two of the analogs
(IYPF and VYPF), while C-terminal amidation reduced the bind-
ing of all peptides exceptVHVF. CombinedN-terminal acetylation
and C-terminal amidation signiﬁcantly reduced apparent binding
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further demonstrating the requirement for the C-terminal car-
boxyl group for ACE2 binding.
IYPF and VYPF were subsequently used to generate a series of
Ang II octapeptide analogs to further explore the relative binding
requirements to ACE2, AT1R, and AT2R. Speciﬁcally, these two
tetrapeptides were grafted onto the N-terminus of Ang II to yield
a range of chimeric Ang II analogs. In addition, β-amino acid
analogs were also synthesized to exploit the selectivity and pro-
teolytic stability effects previously observed (Clayton et al., 2011;
Jones et al., 2011). The results are summarized in Table 6 and
reveal a ladder of selectivity changes within the series of six pep-
tides. Relative to Ang II, peptides with Tyr6 or Tyr6/Val5 both
lost AT1R binding but maintained ACE2 and AT2R binding and
also both exhibited increased helical structure. These results agree
with our previous study (Clayton et al., 2011; Jones et al., 2011)
and others (Magnani et al., 2014) who also observed that changes
at residue 6 in Ang II lead to AT2R-selective ligands. The present
results also further demonstrate that a bulky hydrophobic residue
is equally tolerated by bothACE2 andAT2R. By comparison, when
Pro7 was replaced by β-Pro7 in both of these peptides, there was
a substantial loss in ACE2 binding but AT2R binding was largely
maintained. This change was also accompanied by a loss in appar-
ent helicity suggesting that the selectivity between ACE2, AT1R,
and AT2R can be controlled by both the physicochemical proper-
ties of speciﬁc amino acids in Ang II and also manipulation of the
conformational properties of the peptide. Finally, substitution of
Phe8 with β-Phe8 resulted in a loss of ACE2 binding and a fur-
ther substantial decrease in AT2R binding and the adoption of a
different secondary structure. Binding of Ang II analogs to the
AT2R was therefore less dependent on secondary structure and/or
amino acid side chain presentation compared to AT1R binding.
AT1R binding was therefore more sensitive to structure and/or
side chain presentation as all but one Ang II analog showed mini-
mal AT1R binding and is consistent with previous studies (Miura
and Karnik, 1999; Rosenstrom et al., 2004a).
It is now clear that the central to C-terminal region of Ang
II can be modiﬁed to engineer selectivity of binding to different
Ang II binding partners. Our present results are consistent with
our previous ﬁndings where single β-amino acid substitutions to
Ang II resulted in Ang II analogs which conferred marked selec-
tivity for agonism at AT2R over AT1R (Jones et al., 2011). Our
ﬁndings are also consistent with other studies that demonstrated
the importance of the central region of Ang II for AT2R binding.
For example, substitution of His6 by 4-NH2-Phe6 in Ang II pro-
duced a peptide with high AT2R-to-AT1R selectivity (Speth and
Kim, 1990; Rosenstrom et al., 2004a,b). Others have also shown
that modiﬁcations to the Tyr4-Ile5 residues of Ang II result in
AT2R-selective compounds (Johannesson et al., 2004; Rosenstrom
et al., 2004b). Finally, Tyr6-Ang II has also been shown to bind
selectively to AT2R (Magnani et al., 2014). A general strategy to
designAT1R-, orAT2R-selective ligands for therapeutic application
is to use the key apolar, cyclic and imidazolic binding function-
alities of the central and C-terminal of Ang II as a template for
generating small molecules libraries to be screened for selective
AT receptor binding activity (Agelis et al., 2012, 2013; Sharma,
2014; Veron et al., 2014). Other approaches exploit the conforma-
tional aspects of Ang II-AT receptor interaction to design selective
ligands (Oliveira et al., 2011). Our results provide new information
on the structural determinants for optimal amino acid residues
and functional group combinations for RAS-ligand binding to
inform future peptidomimetic design for both of these design
approaches.
Overall, the binding and stability proﬁle of these stabilized
peptides may modulate hypertensive proﬁle by either provid-
ing a stable Ang II analog that could act on the AT2R without
inactivation or by inhibiting ACE2 and so prolonging the action
of endogenously produced Ang II. Functional assays on these
Ang II peptidomimetics are therefore required to indicate ago-
nist or antagonist activity, together with in vivo studies to proﬁle
the action of these compounds and to elucidate the therapeutic
potential of these compounds, given that cardiovascular tone is
controlled by the action of several proteins including ACE, ACE2,
AT1R, and AT2R.
CONCLUSION
The last decade has seen the discovery of several new com-
ponents of the RAS which is now seen as a balance between
the pro-vasoconstrictor, pro-ﬁbrotic, pro-growth axis and the
pro-vasodilatory, anti-ﬁbrotic, anti-growth arm. Hypertension is
one of the cardiovascular diseases that may cause cardiovascu-
lar remodeling and endothelial dysfunction on top of high blood
pressure. ACE2, AT1R, and AT2R all play a central role in this con-
stantly evolving scenario and our studies provide new insight into
the structure and function of these proteins. In particular, we have
investigated the topographical and structural requirements for the
binding of the C-terminal region of Ang II to ACE2, AT1R, and
AT2R. We employed a focused library approach to characterize
the binding determinants in the Ang II C-terminal tetrapeptide
template IHPF and the results identiﬁed four substitutions that
enhanced apparent binding to ACE2. The Ang II chimeras identi-
ﬁed in this study revealed key residues, side chain functionalities
and structure-binding relationships which can be used to inform
a small molecule drug design approach for more speciﬁc and
selective control cardiovascular function. As such, this type of
peptidomimetic design shows great potential for the production
of research tools to provide insight into the structure and function
of key members of RAS.
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